VKTX

The article compares Novo Nordisk (NVO) and Viking Therapeutics (VKTX) as investment opportunities in the growing obesity-treatment market projected to reach $114 billion by 2030. NVO has established products like Wegovy and Ozempic but faces intensifying competition from Eli Lilly's tirzepatide drugs.

VKTX, a clinical-stage biotech, is advancing VK2735 in phase III studies with promising maintenance data showing 90% weight-loss retention with biweekly dosing. While NVO offers stability with declining earnings, VKTX presents higher-risk, higher-reward potential with a Zacks Rank #2 (Buy) versus NVO's #3 (Hold).

Viking Therapeutics is advancing its weight-loss drug candidates, particularly SC VK2735, through Phase 3 trials with promising clinical results. Under a bullish scenario with $1 billion in 2031 revenue, a $1,000 investment could grow to approximately $1,875 by 2031 (13.4% annualized returns). However, significant risks exist including potential Phase 3 trial failures, increased competition, market growth uncertainties, and potential dilutive financing needs.

Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027.

Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning.